Key Points
- CFO Dominic Piscitelli sold 52,000 shares at an average of $13.51 for a total of $702,520, cutting his stake by about 43% to 68,148 shares (disclosed in an SEC Form 4).
- Despite the insider sale, Oric posted an earnings beat (Q4 EPS of -$0.30 vs. -$0.34) and has seen multiple analyst upgrades — the consensus rating is a Moderate Buy with a $20.20 target (implying roughly 58% upside), including HC Wainwright raising its target to $25.
- Shares trade near $13.50 (1‑year range $3.90–$14.93) and the company remains unprofitable with analysts projecting roughly -$2.17 EPS for the year and a market cap around $1.35 billion.
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CFO Dominic Piscitelli sold 52,000 shares of the company's stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $13.51, for a total transaction of $702,520.00. Following the sale, the chief financial officer directly owned 68,148 shares in the company, valued at $920,679.48. This trade represents a 43.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Dominic Piscitelli also recently made the following trade(s):
- On Tuesday, December 16th, Dominic Piscitelli sold 10,720 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $9.06, for a total value of $97,123.20.
Oric Pharmaceuticals Price Performance
Shares of NASDAQ:ORIC opened at $13.50 on Friday. Oric Pharmaceuticals, Inc. has a 1 year low of $3.90 and a 1 year high of $14.93. The business's 50-day moving average is $10.28 and its 200-day moving average is $10.97. The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of -8.88 and a beta of 1.35.
Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its earnings results on Monday, February 23rd. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.34) by $0.04. Analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current year.
Wall Street Analyst Weigh In
ORIC has been the subject of a number of research reports. Wolfe Research began coverage on shares of Oric Pharmaceuticals in a report on Tuesday, November 18th. They issued a "peer perform" rating for the company. Wedbush reissued an "outperform" rating and set a $20.00 price objective on shares of Oric Pharmaceuticals in a research report on Tuesday. Piper Sandler started coverage on Oric Pharmaceuticals in a research note on Wednesday, January 7th. They set an "overweight" rating and a $22.00 price target on the stock. HC Wainwright increased their price target on Oric Pharmaceuticals from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, JPMorgan Chase & Co. boosted their price objective on Oric Pharmaceuticals from $17.00 to $20.00 and gave the company an "overweight" rating in a report on Tuesday, November 18th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Oric Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $20.20.
Read Our Latest Stock Report on ORIC
Key Stories Impacting Oric Pharmaceuticals
Here are the key news stories impacting Oric Pharmaceuticals this week:
- Positive Sentiment: HC Wainwright raised Q1–Q4 and FY2026 EPS estimates, cut its FY loss forecast to ($1.28) from ($1.52), reiterated a "Buy" rating and set a $25 price target (up from $23). This analyst upgrade and higher target support upside expectations. H.C. Wainwright raises estimates and price target
- Positive Sentiment: Consensus/price-target commentary highlights substantial analyst upside — Zacks notes the mean analyst target implies ~58.4% upside, which can attract momentum buyers. Zacks: analyst mean implies large upside
- Positive Sentiment: Wedbush assigned an "Outperform" rating, adding to bullish analyst sentiment that likely helped lift the shares. Wedbush Outperform
- Positive Sentiment: ORIC reported an earnings beat (Q4 EPS of ($0.30) vs. consensus ($0.34)), a near-term catalyst that pushed the stock higher. The earnings surprise appears to be the immediate driver of today’s rally. Earnings beat and stock reaction
- Neutral Sentiment: Despite upgrades, consensus estimates still show ORIC operating at a multi-quarter loss (current full-year consensus around ($2.17) per share), so upside hinges on continued clinical progress and margin improvements. MarketBeat consensus background
- Negative Sentiment: CFO Dominic Piscitelli sold 52,000 shares at ~$13.51 (about $702.5k), reducing his stake by ~43%; insider selling can be perceived negatively by investors and may moderate price gains. SEC filing: SEC Form 4 — CFO sale
Institutional Trading of Oric Pharmaceuticals
Several institutional investors have recently made changes to their positions in ORIC. Nisa Investment Advisors LLC increased its stake in Oric Pharmaceuticals by 17,300.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,436 shares of the company's stock valued at $25,000 after buying an additional 2,422 shares during the last quarter. Federation des caisses Desjardins du Quebec grew its holdings in shares of Oric Pharmaceuticals by 100.0% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company's stock valued at $33,000 after acquiring an additional 2,000 shares in the last quarter. Assetmark Inc. purchased a new stake in shares of Oric Pharmaceuticals during the third quarter valued at approximately $37,000. Caitong International Asset Management Co. Ltd lifted its holdings in Oric Pharmaceuticals by 184.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company's stock worth $37,000 after acquiring an additional 2,936 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Oric Pharmaceuticals by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company's stock worth $39,000 after purchasing an additional 977 shares during the last quarter. Institutional investors own 95.05% of the company's stock.
About Oric Pharmaceuticals
(
Get Free Report)
Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.
The company's pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
